STOCK TITAN
  1. Home
  2. Sec-filings
  3. LQDA
  4. [144] Liquidia Corp SEC Filing

LQDA (NASDAQ) insiders sell via 10b5-1; $5.76M proposed sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing: Morgan Stanley Smith Barney LLC submitted a notice for the proposed sale of 100,000 shares of common stock of LQDA on 05/14/2026, showing an aggregate value of $5,759,000 and 88,928,099 shares outstanding as of 05/14/2026.

The filing lists multiple completed 10b5-1 sales by Serendipity Biopharma LLC on dates in April–May 2026 (example: 25,000 shares on 05/13/2026 for $1,407,127.50) and a sale by Roger Jeffs on 04/13/2026 for 32,744 shares ($1,256,387.28). The notice reports planned or recent resale activity under an established trading plan.

Positive

  • None.

Negative

  • None.

Insights

Legal snapshot: Form 144 documents proposed/resale transactions under Rule 144 and shows 10b5-1 execution dates.

The filing identifies a proposed sale of 100,000 shares and multiple completed 10b5-1 sales dated in April–May 2026. The notice is a routine disclosure required when affiliates or insiders plan to sell restricted or control securities.

Key dependencies: the sales list an aggregate value $5,759,000 and an outstanding share count of 88,928,099 as of 05/14/2026. Subsequent regulatory filings will show settlement and any remaining restricted holdings.

Market-impact view: multiple scheduled 10b5-1 dispositions are recorded; trading was executed across several dates in Apr–May 2026.

The excerpt lists repeated 10b5-1 sales by Serendipity Biopharma LLC (examples: 25,000 shares on 05/13/2026 for $1,407,127.50) and a 32,744-share sale by Roger Jeffs on 04/13/2026. These are disposition events rather than new issuances.

Cash‑flow treatment and whether the issuer receives proceeds are not specified in the provided excerpt; trading plan references and settlement details will appear in other filings if required.

Proposed sale 100,000 shares as reported on 05/14/2026
Aggregate value shown $5,759,000 associated with the 100,000-share entry dated 05/14/2026
Shares outstanding 88,928,099 shares as of 05/14/2026
Example sale 25,000 shares 05/13/2026 for $1,407,127.50 (10b5-1 sale)
Example sale by Roger Jeffs 32,744 shares 04/13/2026 for $1,256,387.28
10b5-1 regulatory
"10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 05/13/2026 25,000"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
resale financial
"144: Securities Sold During The Past 3 Months"
Resale is the act of selling an item, asset, or security by someone who previously bought it rather than by the original maker or issuer. It matters to investors because resale activity affects how easily an investment can be sold, the price buyers are willing to pay, and the potential profit or loss — like selling a used car: condition, demand and market rules determine what you can get for it.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR

FAQ

What does the LQDA Form 144 report?

It reports proposed and completed sales of common stock by affiliates or insiders. The filing lists a proposed sale of 100,000 shares and multiple 10b5-1 sales between April and May 2026, with example proceeds such as $1,407,127.50 on 05/13/2026.

Who executed the 10b5-1 sales listed in the filing?

The excerpt lists 10b5-1 sales by Serendipity Biopharma LLC and one sale by Roger Jeffs. Examples include Serendipity Biopharma LLC sales of 25,000 shares on 05/13/2026 and Roger Jeffs' sale of 32,744 shares on 04/13/2026.

How much aggregate value is shown for the proposed sale?

The filing shows an aggregate value of $5,759,000 tied to 100,000 shares. The excerpt pairs that aggregate figure with the 05/14/2026 filing date and an outstanding share count of 88,928,099.

Are these sales under a trading plan?

Yes; many entries are labeled as 10b5-1 sales, indicating execution under an established trading plan. The listed transactions include dates and amounts for April–May 2026 executed under those plan entries.

Does the filing say whether the company receives proceeds?

The provided excerpt does not state the recipient of proceeds. The entries identify resale/disposition transactions and dollar amounts but do not specify issuer proceeds or use of funds.